Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

Researchers have achieved impressive results in animal studies with a new weight-loss drug that has no GLP-1-style side ...

Obesity and family practice experts share when it’s safe to prescribe GLP-1 receptor agonists to patients with thyroid ...

All products are independently selected by our editors. If you buy something, we may earn an affiliate commission.

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic ...

Merck & Co. Inc. and Hansoh Pharmaceutical Group Co. Ltd. have entered into an exclusive global license agreement for ...

Blood sugar and insulin levels also depend on the vagus nerve. As blood sugar levels rise, the vagus nerve stimulates the ...

The following is a summary of “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity,” published in the ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...